Recursion Pharmaceuticals (RXRX) Return on Sales (2020 - 2026)

Recursion Pharmaceuticals' Return on Sales history runs 7 years deep, the most recent figure standing at 0.18% for Q1 2026.

• Quarterly Return on Sales fell 4.0% year-over-year to 0.18% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.08% (up 1.0% YoY) and the FY2025 annual result came in at 0.09%, down 1.0% from the prior year.
• Return on Sales was 0.18% for Q1 2026 at Recursion Pharmaceuticals, down from 0.03% in the prior quarter.
• Across five years, Return on Sales topped out at 0.03% in Q4 2025 and bottomed at 0.39% in Q4 2024.
• A 5-year average of 0.11% and a median of 0.09% in 2023 frame the typical range for Return on Sales.
• Annual changes were most pronounced in 2024 — Return on Sales plunged 31 bps — and 2025, when it jumped 36 bps.
• Recursion Pharmaceuticals' Return on Sales stood at 0.05% in 2022, then plunged by 81 bps to 0.09% in 2023, then sank by 361 bps to 0.39% in 2024, then soared by 92 bps to 0.03% in 2025, then slumped by 497 bps to 0.18% in 2026.
• Business Quant data shows RXRX's Return on Sales at 0.18% in Q1 2026, 0.03% in Q4 2025, and 0.31% in Q3 2025.